Drug intelligence / Profile preview

PK071

Development stage: Preclinical
Lead developer: PharmaKure
Modality: Small Molecules
Administration: Oral

Overview

PK071 is a preclinical-stage small molecule therapeutic being developed by PharmaKure for the treatment of Multiple System Atrophy (MSA). It functions as an α-synuclein inhibitor, targeting the pathological accumulation and aggregation of α-synuclein protein, which is a key hallmark of MSA and other synucleinopathies. By inhibiting these aggregates, PK071 aims to mitigate the neurodegenerative processes associated with the disease. The drug is currently in the research and preclinical development phase.

Targets

TauO (Microtubule-associated protein tau oligomer)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PK071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK071.

Explore the full profile